{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-002951","form_type":"8-K","ticker":null,"cik":"0001044378","company_name":"BIOCEPT INC","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.645041+00:00","generated_at":"2026-06-20T18:33:04.750482+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biocept explores strategic alternatives, reduces workforce by 36%, projects $13M cash","bullets":["Commenced evaluation of strategic alternatives including acquisition, merger, asset sale; engaged EF Hutton as advisor.","Workforce reduction of approximately 36% expected in Q1 2023; severance and related costs estimated at $0.6M.","Projects year-end 2022 cash balance of about $13M; plans to cease COVID-19 testing at end of January 2023.","CNSide assay remains a focus but company seeks to extend cash runway amid exploration.","No assurance of successful strategic outcome; no further updates unless board approves a specific course."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-002951","json":"https://secwatch.observer/filing/0001193125-23-002951.json","markdown":"https://secwatch.observer/filing/0001193125-23-002951.md","text":"https://secwatch.observer/filing/0001193125-23-002951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523002951/0001193125-23-002951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523002951/d423520d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:33:04.750482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f016266e825286b27959537ac32dacdfeee7694","claim":"BIOCEPT INC announced a restructuring with charges of approximately $0.6 million (approximately 36%).","evidence_excerpt":"the Company is implementing a restructuring plan that will result in a reduction in the Company’s workforce by approximately 36%. The reduction in force is expected to be completed during the first quarter of 2023. The Company estimates that it will incur charges of approximately $0.6 million for severance and other employee termination-related costs in the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523002951/0001193125-23-002951-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.6 million"},{"label":"Headcount","value":"approximately 36%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}